Alfacell (ACEL) Announces CFO Resigns
More News related to ACEL
- Alfacell (ACEL) Announces CFO Resigns
- Alfacell (ACEL) Reports Q1 Loss of $0.06
- Alfacell (ACEL) Reports Better-Than-Expected Q4 Loss
- Alfacell (ACEL) Announces Paper in Cell Cycle Reports ONCONASE(R) Targets siRNA
- Alfacell (ACEL) Receives Delisting Notification from NASDAQ
More News related to Management Changes
- Adeona Pharma (AEN) Appoints James Kuo as CEO and President
- Cowen Group (COWN) to Integrate Businesses to Streamline Operations
Alfacell Corporation (Nasdaq: ACEL) announced that Lawrence A. Kenyon, its president, chief financial officer and corporate secretary, will resign as an employee of Alfacell as of today. Mr. Kenyon will remain on the board of directors of Alfacell and will also serve as acting president, chief financial officer and corporate secretary until at least January 31, 2009. Mr. Kenyon has accepted a full time position as executive vice president of finance at Par Pharmaceutical, Inc., effective December 15, 2008.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc.
Related Categories
Management ChangesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
